Male contraception startup closes $92.5M Series B; Novartis bets on actinium
💸 Funding male contraception: Contraline closed a $92.5 million Series B financing to support a Phase 3 study of a male contraceptive dubbed NES/T. The daily t...
💸 Funding male contraception: Contraline closed a $92.5 million Series B financing to support a Phase 3 study of a male contraceptive dubbed NES/T. The daily treatment is a gel rubbed on the shoulders and ...